Fig. 1. The role of anti-obesity medications on diabetes complication risk management. Data from XENDOS (orlistat), CONQUER (phentermine/topiramate extended-release [ER]), BLOOM (lorcaserin), COR (naltrexone SR/bupropion SR), and SCALE (liraglutide). ER, extended-release; SR, sustained release; PP2, postprandial 2 hour-plasma glucose; FPG, fasting plasma glucose; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; XENDOS, Xenical in the Prevention of Diabetes in Obese Subjects; COR, Contrave Obesity Research.
© JOMES
